Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BioAtla (BCAB) Stock Price & Analysis
117 Followers
BCAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.24 - $12.15
Previous Close$3.15
Volume276.49K
Average Volume (3M)499.25K
Market Cap
$144.43M
Enterprise Value-$44.65M
Total Cash (Recent Filing)$192.69M
Total Debt (Recent Filing)$3.61M
Price to Earnings (P/E)-1.2
Beta2.08
Next Earnings
Aug 10, 2023EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding47,667,516
10 Day Avg. Volume293,753
30 Day Avg. Volume499,247
Standard Deviation0.40
R-Squared0.00106
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$12.50Price Target Upside276.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
BioAtla News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $2.23 and its highest was $12.15 in the past 12 months.
What is BioAtla’s market cap?
Currently, no data Available
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Aug 10, 2023 which is in 69 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on May 11, 2023. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.604 by $0.024.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -$0.66.
How many shares outstanding does BioAtla have?
BioAtla has 47,667,515 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.604. Following the earnings report the stock price went up 14.33%.
Which hedge fund is a major shareholder of BioAtla?
Among the largest hedge funds holding BioAtla’s share is Woodline Partners LP. It holds BioAtla’s shares valued at N/A.
---
BioAtla Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (276.51% Upside)
$12.50 (276.51% Upside)
Hedge Fund Trend
Decreased
By 45.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $148.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.70%
12-Months-Change
Fundamentals
Return on Equity
-63.32%
Trailing 12-Months
Asset Growth
-11.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
---
Top 5 ETFs holding BCAB
iShares NASDAQ US Biotechnology UCITS ETF
$67.83K
Invesco Nasdaq Biotechnology ETF
$2.77K
iShares Core S&P Total U.S. Stock Market ETF
$139.05
Up to five ETFs with an Outperform Smart Score that hold BCAB. The ETFs are listed according to market value of BCAB within the ETF
---
Compass Therapeutics
―
Kezar Life Sciences
―
Coherus Biosciences
―
Caribou Biosciences
―
---